Market Overview

Credit Suisse Believes Top Line Growth Matters More Than Margins For Stericycle

Share:

In a report published Monday, Credit Suisse analyst Hamzah Mazari reiterated an Outperform rating and $140.00 price target on Stericycle (NASDAQ: SRCL).

In the report, Credit Suisse noted, “We believe that operating leverage given lack of infrastructure pre-PSC deal should lead to much higher than expected earnings power over the next 12-16 months. Recall that SRCL can run StrongPak through PSC infrastructure and cut out third party treatment/disposal costs (i.e. had 1 Part B facility vs 13 post deal) in addition to better optimizing route density/logistics. Our sense is that 12 cents of 2015 full year EPS accretion is low based on our channel checks and past environmental deals.”

Stericycle closed on Thursday at $119.23.

Latest Ratings for SRCL

DateFirmActionFromTo
Feb 2020BairdMaintainsNeutral
Nov 2019RBC CapitalInitiates Coverage OnOutperform
Nov 2019JefferiesInitiates Coverage OnHold

View More Analyst Ratings for SRCL
View the Latest Analyst Ratings

 

Related Articles (SRCL)

View Comments and Join the Discussion!

Posted-In: Credit Suisse Hamzah MazariAnalyst Color Reiteration Analyst Ratings

Latest Ratings

StockFirmActionPT
RIGRF LaffertyMaintains5.0
NOVRF LaffertyMaintains13.0
WSCDA DavidsonMaintains19.0
ITTDA DavidsonReiterates70.0
NOWGoldman SachsMaintains376.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com